Allozyne, Inc.

Calculating rank

USPTO Granted Patents = 4

% Expired Patents = 50.0

Forward Citations = 51

Loading Chart...

8 inventors (with patents filed for the assignee):

Kenneth H Grabstein (4 out of 37 patents)

Natalie Winblade Nairn (3 out of 11 patents)

Aijun Wang (2 out of 9 patents)

4. Deepshikha Datta (2 out of 5 patents)

5. Stephen McCraith (2 out of 3 patents)

6. Thomas Graddis (2 out of 8 patents)

7. David A Tirrell (1 out of 21 patents)

8. Andrea Wang (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 10407482 - Amino acid substituted molecules (2019-09-10),

2. 8568706 - Modified human interferon-beta polypeptides (2013-10-29),

3. 7829659 - Methods of modifying polypeptides comprising non-natural amino acids (2010-11-09),

4. 7632492 - Modified human interferon-β polypeptides (2009-12-15),

Company Overview

Allozyne, Inc. is a biotechnology company that specializes in the development of protein therapeutics for the treatment of autoimmune and inflammatory diseases. The company's proprietary technology platform allows for the design and engineering of novel protein drugs with improved efficacy and safety profiles. Allozyne's mission is to address unmet medical needs and improve the lives of patients through innovative drug development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

4 Patents

#423 in Seattle, WA

#1,465 in Washington

#60,704 in US

Seattle, WA, United States of America

Allozyne, Inc.

Forward Citations = 51

8 inventors:

Kenneth H Grabstein (4 out of 37 patents)

Natalie Winblade Nairn (3 out of 11 patents)

Aijun Wang (2 out of 9 patents)

4. Deepshikha Datta (2 out of 5 patents)

5. Stephen McCraith (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Allozyne, Inc.. Retrieved from https://idiyas.com/company/allozyne

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]